Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its ...

Libevitug works by blocking hepatitis B and D viruses from entering liver cells, targeting the PreS1 domain of the viral ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

Chinese biotech Huahui Health has won conditional approval for Libevitug (libevitug) to treat adults with chronic hepatitis D ...

Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its ...

China's drug regulator has granted conditional approval to Huahui Health's Libevitug injection for the treatment of the ...

The Hepatitis B Co-care Scheme, allowing eligible individuals to receive a hepatitis B risk assessment, screening and ...

(Yicai) Jan. 21 -- Chinese innovative pharmaceutical company Kawin Technology plummeted today after withdrawing its ...

Authorities say screening will cover people born in Hong Kong in or before 1988 with family members or sexual partners who ...

Mirum Pharmaceuticals’ acquisition of Bluejay Therapeutics adds brelovitug to its pipeline, positioning the company for a potential first approved treatment for chronic hepatitis delta virus while ...

Erin Seacat works the syringe exchange window on Jan. 13, on the lower level of Damien Center in Indianapolis. The free and ...

Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer and continues to be a major cause of cancer ...